Overview
9amHealth offers virtual cardiometabolic care to prevent and manage chronic conditions such as diabetes, obesity, high cholesterol, and hypertension. Its platform provides personalized treatment plans, access to endocrinologists and pharmacists, at-home lab testing, connected medical devices, and prescription delivery, all through a virtual care experience with a step-therapy approach that starts with lifestyle changes and generics before considering GLP-1s when appropriate. The company differentiates itself with leadership from mySugr’s founders, a holistic, whole-body care model, and partnerships with large pharma and pharmacy networks to expand access to affordable medications. Its goal is to make cardiometabolic care more accessible and effective by combining remote monitoring, personalized care, and affordable medications to improve patient outcomes.
Work here?Claim your company
Simplify's take
What believers are saying
- May 13, 2026 funding followed $50M savings across two Fortune 100 employers.
- March 4, 2026 Withings partnership deepens remote monitoring and engagement for obesity care.
- June 9, 2026 SmithRx included 9amHealth in employer GLP-1 partner ecosystem.
What critics are saying
- PBMs like SmithRx commoditize 9amHealth, squeezing pricing and margin by 2027.
- Employer GLP-1 benefit tightening hits demand if savings proof weakens after 2026.
- If chronic-care expansion stalls, 9amHealth stays a niche virtual clinic without durable moat.
What makes 9amHealth unique
- 9amHealth combines endocrinology, labs, devices, and meds in one cardiometabolic workflow.
- Founders Frank Westermann and Anton Kittelberger built mySugr, acquired by Roche in 2017.
- May 13, 2026 Series B from Define Ventures funded expansion beyond cardiometabolic care.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards